Clinical Textbook of Addictive Disorders 3rd ed - R. Frances, S. Miller, A. Mack (Guilford, 2005) WW

130 III. SUBSTANCES OF ABUSEbupropion SR recipients than for placebo recipients (156 vs. 65 days), andweight gain was significantly less in the bupropion SR group at study weeks 52(3.8 vs. 5.6 kg) and 104 (4.1 vs. 5.4 kg). Predictors of successful relapse prevention(in addition to assignment to bupropion SR treatment) were lower baselinesmoking rates, a Fagerstrom Tolerance Questionnaire score < 6, and initiationof smoking at an older age (Hurt et al., 2002).Hurt and colleagues (2003) studied the efficacy of bupropion SR (1) forpreventing relapse in adult smokers who quit smoking with transdermal nicotinepatch therapy and (2) for quitting smoking in smokers who failed to quiton the patch. At completion of nicotine patch therapy, nonsmoking participantswere assigned to bupropion SR or placebo for 6 months (relapse prevention),and smoking participants were assigned to bupropion SR or placebo for 8weeks of treatment. Of 578 subjects, 31% were abstinent at the end of nicotinepatch therapy. Of those not smoking at the end of initial patch treatment, 28and 25% were not smoking at 6 months (end of medication phase) forbupropion SR and placebo, respectively. For those still smoking at the end ofnicotine patch therapy, 3.1 and 0.0% stopped smoking with bupropion SR andplacebo, respectively. Hurt and colleagues concluded that bupropion SR neitherreduced relapse to smoking in smokers who stopped smoking with the nicotinepatch nor initiated abstinence among smokers who failed to stop smokingon the patch.REFERENCESAhluwalia, J. S., Harris, K. J., Catley, D., Okuyemi, K. S., & Mayo, M. S. (2002). Sustainedrelease bupropion for smoking cessation in African-Americans: A randomizedcontrolled trial. JAMA, 228, 468–474.Aitken, P. (1980). Peer group pressures, parental controls and cigarette smoking amongten- to- fourteen year olds. Br J Soc Clin Psychol, 19, 141–146.American Academy of Pediatrics Committee on Substance Abuse. (2001). Tobacco’stoll: implications for the pediatrician. Pediatrics, 107, 794–798.American Cancer Society. (1986). Facts and figures on smoking, 1976–1986 (PublicationNo. 5650-LE). New York: Author.American Cancer Society. (2003). Cancer facts and figures 2003. Atlanta: Author.American Lung Association. (2003). Key facts about tobacco use. Retrieved on April15, 2003, from www.lungusa.orgAmerican Psychiatric Association. (1994). Diagnostic and statistical manual of mental disorders(4th ed.). Washington, DC: Author.American Psychiatric Association. (1996). Practice guidelines for the treatment ofpatients with nicotine dependence. Am J Psychiatry, 153(Suppl), 1–31.American Psychiatric Association. (2000). Diagnostic and statistical manual of mental disorders(4th ed., text rev.). Washington, DC: Author.Anthonisen, N. R., Connett, J. E., Kiley, J. P., Altose, M. D., Bailey, W. C., Buist, A.S., et al. (1994). Effects of smoking intervention and use of an inhaled anti-